Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C3AR1 | Q16581 | 1/20 | 0.55 |
| ▸ | GNPAT | O15228 | 1/20 | 0.54 |
| ▸ | FNTA | P49354 | 3/20 | 0.53 |
| ▸ | FNTB | P49356 | 3/20 | 0.53 |
| ▸ | PGGT1B | P53609 | 3/20 | 0.53 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.49 |
| ▸ | CTSC | P53634 | 1/20 | 0.49 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.48 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.48 |
| ▸ | ALPI | P09923 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | XIAP | P98170 | 1/20 | 0.48 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.48 |
| ▸ | MME | P08473 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6047680 | 1.00 | C3AR1 (0.55) | C3AR1GNPATFNTAFNTBPGGT1B | |
| SCHEMBL27757798 | 1.00 | C3AR1 (0.55) | C3AR1GNPATFNTAFNTBPGGT1B | |
| SCHEMBL29406246 | 0.92 | ERAP2 (0.55) | C3AR1GNPATFNTAFNTBPGGT1B | |
| SCHEMBL31476469 | 0.91 | FNTA (0.50) | C3AR1GNPATFNTAFNTBPGGT1B | |
| SCHEMBL29404204 | 0.90 | GNPAT (0.53) | GNPATKISS1RERAP2LNPEP | |
| SCHEMBL1711701 | 0.90 | GNPAT (0.52) | GNPATFNTAFNTBPGGT1BKISS1R | |
| SCHEMBL29540393 | 0.90 | GNPAT (0.52) | GNPATFNTAFNTBPGGT1BKISS1R | |
| SCHEMBL1711691 | 0.90 | GNPAT (0.52) | GNPATFNTAFNTBPGGT1BKISS1R | |
| SCHEMBL5966602 | 0.90 | GNPAT (0.52) | GNPATFNTAFNTBPGGT1BKISS1R | |
| SCHEMBL5966594 | 0.90 | GNPAT (0.52) | GNPATFNTAFNTBPGGT1BKISS1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1047 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144882-A1 | ANTI-NECTIN-4 ANTIBODY DRUG CONJUGATE AND USE THEREOF | BIO-THERA SOLUTIONS, LTD. (CN) | 2026-05-28 | — | — | US | claimed |
| CN-122028936-A | Antibody-drug conjugates | ADC疗法责任有限公司 | 2026-05-12 | — | — | CN | claimed |
| US-20260124212-A1 | MAYTANSINOID DERIVATIVES WITH SELF-IMMOLATIVE PEPTIDE LINKERS AND CONJUGATES THEREOF | IMMUNOGEN INC (US) | 2026-05-07 | — | — | US | claimed |
| US-20260014264-A1 | SPECIFIC TOPOISOMERASE INHIBITOR, USE AS ANTIBODY DRUG CONJUGATE, AND PREPARATION METHOD THEREFOR | BIOBRICS LIFE SCIENCE (NANTONG) CO., LTD. (CN) | 2026-01-15 | — | — | US | claimed |
| US-20260008848-A1 | ANTI-NECTIN-4 ANTIBODY, AND ANTIBODY-DRUG CONJUGATE AND USE THEREOF | BIO THERA SOLUTIONS LTD (CN) | 2026-01-08 | — | — | US | claimed |
| US-20260007763-A1 | PEGYLATED ANTIBODY HYDROXYL-BEARING DRUG CONJUGATE | SHENZHEN ENDURING BIOTECH, LTD. (CN) | 2026-01-08 | — | — | US | claimed |
| US-20260007756-A1 | COMPOUND AND USE THEREOF | COHERENT BIOPHARMA SUZHOU LTD (CN) | 2026-01-08 | — | — | US | claimed |
| US-20250381283-A1 | METHOD FOR TREATING SOLID TUMOR | BIO THERA SOLUTIONS LTD (CN) | 2025-12-18 | — | — | US | claimed |
| EP-4663205-A1 | POLYMER-DRUG CONJUGATE, INTERMEDIATE THEREOF, AND USE THEREOF | Shanghai Best-Link Bioscience, LLC (CN) | 2025-12-17 | — | — | EP | claimed |
| US-20250333498-A1 | ANTI-CLDN18.2 ANTIBODY, AND ANTIBODY-DRUG CONJUGATE AND USE THEREOF | BIO THERA SOLUTIONS LTD (CN) | 2025-10-30 | — | — | US | claimed |
| WO-2022058395-A1 | ANTIBODY-EXATECAN CONJUGATES | SYNAFFIX B.V. (NL) | 2022-03-24 | — | — | WO | claimed |
| CN-114222752-A | Anti-tissue factor antibody-drug conjugates and related methods | 伊科尼克治疗公司 | 2022-03-22 | — | — | CN | claimed |
| CN-114222756-A | Biparatopic FR-alpha antibodies and immunoconjugates | 伊缪诺金公司 | 2022-03-22 | — | — | CN | claimed |
| CN-114174317-A | Amatoxin antibody-drug conjugates and uses thereof | 海德堡医药研究有限责任公司 | 2022-03-11 | — | — | CN | claimed |
| EP-3962935-A1 | BIPARATOPIC FR-ALPHA ANTIBODIES AND IMMUNOCONJUGATES | Immunogen, Inc. (US) | 2022-03-09 | — | — | EP | claimed |
| EP-3941527-A1 | METHODS OF PREPARING CELL-BINDING AGENT-DRUG CONJUGATES | ImmunoGen, Inc. (US) | 2022-01-26 | — | — | EP | claimed |
| CN-100372570-C | Pharmaceutical compositions comprising polysaccharide conjugates for inhibiting the metastsis or preventing the recurrence of maligant tumor | TANABE SEIYAKU CO (JP) | 2008-03-05 | — | — | CN | claimed |
| CN-1545423-A | Pharmaceutical compositions comprising polysaccharide conjugates for inhibiting the metastsis or preventing the recurrence of maligant tumor | ������ҩ��ʽ���� | 2004-11-10 | — | — | CN | claimed |
| EP-1418947-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POLYSACCHARIDE CONJUGATES FOR INHIBITING THE METASTASIS OR PREVENTING THE RECURRENCE OF MALIGNANT TUMOR | TANABE SEIYAKU CO., LTD. (JP) | 2004-05-19 | — | — | EP | claimed |
| WO-2003015826-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POLYSACCHARIDE CONJUGATES FOR INHIBITING THE METASTSIS OR PREVENTING THE RECURRENCE OF MALIGANT TUMOR | TANABE SEIYAKU CO., LTD. (JP) | 2003-02-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260014264-A1 | SPECIFIC TOPOISOMERASE INHIBITOR, USE AS ANTIBODY DRUG CONJUGATE, AND PREPARATION METHOD THEREFOR | TOP1, TOP2A, TOP2B | C3AR1 1996/4885GNPAT 1939/4885FNTA 786/4885 |
| US-20260008848-A1 | ANTI-NECTIN-4 ANTIBODY, AND ANTIBODY-DRUG CONJUGATE AND USE THEREOF | NECTIN4, VSIG8, IGSF11 | C3AR1 1176/4885GNPAT 3927/4885FNTA 4290/4885 |
| US-20260144882-A1 | ANTI-NECTIN-4 ANTIBODY DRUG CONJUGATE AND USE THEREOF | NECTIN4, CD22, NGFR | C3AR1 7/4885GNPAT 2519/4885FNTA 3390/4885 |
| US-20260007763-A1 | PEGYLATED ANTIBODY HYDROXYL-BEARING DRUG CONJUGATE | PTMS, ACP1, CD2 | C3AR1 1083/4885GNPAT 1213/4885FNTA 3665/4885 |
| US-20260007756-A1 | COMPOUND AND USE THEREOF | FOLH1, TRPV6, FOLR1 | C3AR1 1811/4885GNPAT 3926/4885FNTA 2109/4885 |
| US-20250333498-A1 | ANTI-CLDN18.2 ANTIBODY, AND ANTIBODY-DRUG CONJUGATE AND USE THEREOF | CNTN1, EPCAM, SLC22A8 | C3AR1 2177/4885GNPAT 3083/4885FNTA 3555/4885 |
| US-20260124212-A1 | MAYTANSINOID DERIVATIVES WITH SELF-IMMOLATIVE PEPTIDE LINKERS AND CONJUGATES THEREOF | VEGFA, VIP, AREG | C3AR1 609/4885GNPAT 4828/4885FNTA 4337/4885 |
| US-20250381283-A1 | METHOD FOR TREATING SOLID TUMOR | TPM4, TPM3, TPST2 | C3AR1 2091/4885GNPAT 1696/4885FNTA 2071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.